Sitafloxacin + Moxifloxacin Hydrochloride
ApprovedCompleted 3 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
COPD Exacerbation Acute
Conditions
COPD Exacerbation Acute
Trial Timeline
Aug 10, 2022 → Sep 25, 2024
NCT ID
NCT05400369About Sitafloxacin + Moxifloxacin Hydrochloride
Sitafloxacin + Moxifloxacin Hydrochloride is a approved stage product being developed by Daiichi Sankyo for COPD Exacerbation Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT05400369. Target conditions include COPD Exacerbation Acute.
What happened to similar drugs?
20 of 20 similar drugs in COPD Exacerbation Acute were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05400369 | Approved | Completed |
Competing Products
20 competing products in COPD Exacerbation Acute